高內涵篩檢市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、應用、最終用戶、地區和競爭格局分類），2021-2031年

全球高內涵篩檢市場預計將從 2025 年的 12.8 億美元成長到 2031 年的 20.2 億美元，複合年成長率達到 7.89%。

高內涵篩檢(HCS) 將自動化顯微鏡技術與先進的影像分析結合，能夠量化細胞模型中的表現型變異，從而同時評估眾多生物學參數。這種分析能力對於在藥物研發早期階段發現有前景的候選藥物並確定其毒性特徵至關重要。該市場的成長主要源於降低藥物研發高失敗率的需求以及對更具預測性和生理相關性的檢測方法的需求。產業對創新的大量投資也支撐了這一成長勢頭；例如，歐洲製藥工業協會聯合會 (EFPIA) 報告稱，歐洲製藥業將在 2024 年投入 550 億歐元用於研發。

儘管成長要素強勁，但市場仍面臨與數據管理和分析複雜性相關的重大障礙。由於每台篩檢都會產生Terabyte的高解析度影像數據，處理和儲存這些資訊所需的基礎設施和專業的生物資訊技術構成了一個資源密集的瓶頸。這種技術難題推高了整體擁有成本，並有可能阻礙小規模實驗室和研究機構採用高內涵成像技術。

市場促進因素

製藥和生技領域研發投入的不斷成長是全球高內涵篩檢市場的主要驅動力。面對專利到期，各公司正將資金集中投入早期藥物發現基礎設施建設，以補充其研發管線，並投資收購對高通量檢測至關重要的自動化顯微鏡平台。諾華公司2025年4月發布的新聞稿《諾華將擴大在美國的研發和生產規模》就鮮明地反映了這一趨勢。新聞稿宣布了一項為期五年、總額達230億美元的戰略投資，旨在加強研發能力，凸顯了該行業對先進篩檢技術在高效識別候選治療藥物方面的依賴。

人工智慧 (AI) 和機器學習的融合進一步加速了這些技術的應用，解決了影像資料分析中的關鍵瓶頸。現代篩檢系統產生大量資料集，傳統方法難以大規模處理。因此，人工智慧演算法對於快速表現型分析至關重要。這種技術融合正在吸引大量資金用於藥物發現的數位化。例如，在2025年3月題為「Isomorphic Labs宣布獲得6億美元資金籌措」的新聞稿中，Isomorphic Labs宣布已獲得6億美元融資，用於擴展其用於新型治療藥物設計的AI引擎。這些工具的影響在監管效率的提高上顯而易見；2025年，美國食品藥物管理局(FDA) 藥物評價與研究中心報告稱，上年度已核准50種新藥上市，這表明篩檢的化合物已成功實用化。

市場挑戰

全球高內涵篩檢市場在資料管理和分析複雜性方面面臨許多挑戰。由於篩檢平台會產生Terabyte的高解析度影像，龐大的資訊量造成了營運瓶頸，需要大規模的儲存基礎設備和專業的生物資訊技術。這顯著增加了整體擁有成本，使得這項技術對於資金有限的小規模實驗室和研究機構而言難以負擔。因此，處理這些資料集所需的高資源消耗阻礙了高內涵技術的廣泛應用，直接限制了其在成本敏感領域的市場擴張。

處理複雜生物數據方面普遍存在的行業難題進一步加劇了這種技術壁壘。根據皮斯托亞聯盟（Pistoia Alliance）的數據顯示，52%的生命科學專業人士認為「低品質且管理不善的資料集」是2024年採用先進分析技術的主要障礙。這項數據凸顯了數據挑戰的嚴峻性，因為各機構都在努力維護有效篩檢所需的數位化環境。如果潛在用戶無法克服這些數據處理障礙，他們將被迫放棄採用高內涵分析方法，從而減緩市場的整體成長速度。

市場趨勢

微流體晶片器官篩檢技術的興起標誌著檢測方法向生理相關性檢測的關鍵轉變，這種檢測方法比傳統的2D培養方法更能有效地模擬人體組織結構。這一趨勢的根本驅動力在於業界迫切需要以人為中心的系統取代動物模型，以便在藥物研發早期階段準確預測藥物的毒性和療效。監管機構認知到微生理系統在安全性評估方面具有更優的預測效度，因此正在積極推動這一轉變。根據美國食品藥物管理局（FDA）於2025年4月發布的題為「FDA宣布計劃逐步取消單株抗體和其他藥物的動物試驗要求」的新聞稿，該機構已正式推出藍圖，以與人體相關的方法取代動物試驗，尤其強調推廣使用晶片器官系統來提高藥物安全性並降低研發成本。

同時，CRISPR-Cas9基因編輯技術與高內涵檢測的結合，透過實現對基因功能的無偏差、大規模分析，正在革新功能基因體學。將精準的基因操作與表現型成像相結合，使研究人員能夠將特定的基因突變與細胞表現型直接關聯起來，從而促進目標的可靠識別和檢驗。這種方法超越了簡單的化合物篩檢，以前所未有的規模提供了對疾病路徑機制的深入理解。正如2025年7月麻省理工學院新聞報導《科學家應用光學混合CRISPR篩檢鑑定新型伊波拉候選藥物》報導的那樣，研究人員利用高內涵成像技術篩檢了約4000萬個經CRISPR基因編輯破壞的人類細胞，並成功鑑定了數百種能夠改變病毒感染水平的宿主蛋白。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球高內涵篩檢市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品分類（設備、耗材、軟體、服務）
  • 依應用領域（篩檢、複篩檢、標靶辨識與檢驗、毒性測試、化合物分析等）
  • 依最終用戶（製藥/生技公司、學術/政府機構、合約研究組織）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美高內涵篩檢市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲高內涵篩檢市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區高內涵篩檢市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東與非洲高內涵篩檢市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲高內涵篩檢市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球高內涵篩檢市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Danaher Corporation
• Perkinelmer Inc.
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• Yokogawa Electric Corporation
• Merck KGaA
• Tecan Group Ltd.
• BioTek Instruments, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global High Content Screening Market is projected to expand from USD 1.28 Billion in 2025 to USD 2.02 Billion by 2031, achieving a CAGR of 7.89%. High Content Screening (HCS) combines automated microscopy with sophisticated image analysis to quantify phenotypic variations in cellular models, facilitating the simultaneous assessment of numerous biological parameters. This analytical capacity is crucial for detecting viable drug candidates and defining toxicity profiles during the early stages of development. The market is primarily propelled by the necessity to lower high attrition rates in drug discovery and the demand for assays that are more predictive and physiologically relevant. This momentum is underpinned by significant industry spending on innovation; for instance, the European Federation of Pharmaceutical Industries and Associations reported that the pharmaceutical sector invested €55 billion in research and development across Europe in 2024.

Despite these powerful growth drivers, the market encounters a major obstacle related to the complexity of data management and analysis. The production of terabytes of high-resolution image data during each screen creates a bottleneck, as the infrastructure and specialized bioinformatics expertise needed to process and store this information are resource-heavy. This technical difficulty raises the total cost of ownership and threatens to hinder the adoption of high content technologies within smaller laboratories and research institutions.

Market Driver

Increasing investments in pharmaceutical and biotechnology R&D act as the primary catalyst for the Global High Content Screening Market. Faced with patent expirations, companies are directing capital toward early-stage discovery infrastructure to replenish their pipelines, funding the acquisition of automated microscopy platforms essential for high-throughput assays. This trend is highlighted by Novartis's April 2025 press release, 'Novartis to Expand US-Based R&D and Manufacturing,' which announced a strategic commitment of $23 billion over five years to enhance research capabilities, underscoring the sector's reliance on advanced screening for the efficient identification of therapeutic candidates.

The adoption of these technologies is further accelerated by the integration of artificial intelligence and machine learning, which address critical bottlenecks in image data analysis. Modern screening systems produce massive datasets that traditional methods cannot process at scale; consequently, AI algorithms have become indispensable for rapid phenotypic profiling. This technological convergence is attracting significant capital aimed at digitizing drug discovery. For example, Isomorphic Labs announced in a March 2025 press release, 'Isomorphic Labs announces $600 million funding,' that it had secured $600 million to expand its AI engine for designing novel therapeutics. The impact of these tools is evident in regulatory productivity; the U.S. Food and Drug Administration's Center for Drug Evaluation and Research reported in 2025 that 50 novel drugs were approved in the preceding year, demonstrating the successful translation of screened compounds.

Market Challenge

The Global High Content Screening Market confronts a significant hurdle regarding the complexity of data management and analysis. Since screening platforms generate terabytes of high-resolution imagery, the immense volume of information creates an operational bottleneck that necessitates extensive storage infrastructure and specialized bioinformatics expertise. This requirement drastically inflates the total cost of ownership, rendering the technology financially impractical for smaller laboratories and research institutions with limited capital. Consequently, the high resource intensity needed to process these datasets restricts the broader adoption of high-content technologies, directly limiting market expansion in cost-sensitive sectors.

This technical barrier is emphasized by widespread industry difficulties in handling complex biological data. According to the Pistoia Alliance, in 2024, 52% of life science professionals identified low-quality and poorly curated datasets as the main obstacle to implementing advanced analytical technologies. This statistic illustrates the magnitude of the data challenge, as organizations struggle to maintain the digital environment necessary for effective screening. When potential users cannot overcome these data processing obstacles, they are forced to forego high-content methods, thereby slowing the overall growth trajectory of the market.

Market Trends

The rise of microfluidic organ-on-chip screening technologies marks a pivotal shift toward physiologically relevant assays that mimic human tissue architecture more effectively than traditional 2D cultures. This trend is fundamentally driven by the industry's urgent need to replace animal models with human-centric systems that can accurately predict drug toxicity and efficacy earlier in the pipeline. Regulatory bodies are actively catalyzing this transition, acknowledging that microphysiological systems offer superior predictive validity for safety assessments. According to the U.S. Food and Drug Administration's April 2025 press release, 'FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs,' the agency formally introduced a roadmap to replace animal testing with human-relevant methods, specifically promoting the use of organ-on-a-chip systems to improve drug safety and reduce R&D costs.

Simultaneously, the incorporation of CRISPR-Cas9 gene editing into high content assays is revolutionizing functional genomics by enabling the unbiased, large-scale interrogation of gene function. By combining precise genetic perturbations with phenotypic imaging, researchers can now directly link specific genetic alterations to cellular phenotypes, facilitating robust target identification and validation. This approach moves beyond simple compound screening to provide a deep mechanistic understanding of disease pathways at a scale previously unattainable. As noted by MIT News in July 2025 in the article 'Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets,' researchers successfully utilized high-content imaging to screen approximately 40 million CRISPR-perturbed human cells, identifying hundreds of host proteins that alter viral infection levels.

Key Market Players

• Danaher Corporation
• Perkinelmer Inc.
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• Yokogawa Electric Corporation
• Merck KGaA
• Tecan Group Ltd.
• BioTek Instruments, Inc.

Report Scope

In this report, the Global High Content Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

High Content Screening Market, By Product

• Instruments
• Consumables
• Software
• Services

High Content Screening Market, By Application

• Primary and Secondary Screening
• Target Identification & Validation
• Toxicity Studies
• Compound Profiling
• Others

High Content Screening Market, By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Government Institutions
• Contract Research Organization

High Content Screening Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global High Content Screening Market.

Available Customizations:

Global High Content Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global High Content Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables, Software, Services)
  • 5.2.2. By Application (Primary and Secondary Screening, Target Identification & Validation, Toxicity Studies, Compound Profiling, Others)
  • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic and Government Institutions, Contract Research Organization)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America High Content Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States High Content Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada High Content Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico High Content Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe High Content Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany High Content Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France High Content Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom High Content Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy High Content Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain High Content Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific High Content Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China High Content Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India High Content Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan High Content Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea High Content Screening Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia High Content Screening Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa High Content Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia High Content Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE High Content Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa High Content Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America High Content Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil High Content Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia High Content Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina High Content Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global High Content Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Perkinelmer Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. Agilent Technologies, Inc.
• 15.6. Bio-Rad Laboratories Inc.
• 15.7. Yokogawa Electric Corporation
• 15.8. Merck KGaA
• 15.9. Tecan Group Ltd.
• 15.10. BioTek Instruments, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer